Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type I Transcript
Good afternoon, everyone. Thank you for joining us today for this RNAi roundtable, where we'll be discussing lumasiran in development for the treatment of primary hyperoxaluria Type 1. I'm Josh Brodsky, Director of Investor Relations and Corporate Communications at Alnylam.
With me today are Pritesh Gandhi, Vice President and General Manager of the lumasiran program; Tracy McGregor, Senior Director of Clinical Research; and Dr. Michael Somers, Associate Chief of the division of Nephrology at Boston Children's Hospital and Harvard Medical School.
Before I hand it over to Pritesh, let me start with a few brief comments. Today's RNAi roundtable is the third in a series of roundtable webinars that we're hosting this summer and early fall to review progress across our various programs.
Today's event is expected to run approximately 75 minutes. Pritesh will moderate a Q&A session at the conclusion of the presentations. And if you'd like to submit a question, you can do so at any time
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
